Mohammad Yasin Zamanian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mohammad Yasin Zamanian has a total of 243 co-authors. Here are the top co-authors by number of shared publications:
Maryam Golmohammadi
Department of Ophthalmology David Geffen School of Medicine Los Angeles California USA
29 shared publicationsAhmed Hjazi
Department of Medical Laboratory Sciences, College of Applied Medical Sciences Prince Sattam bin Abdulaziz University Al‐Kharj Saudi Arabia
11 shared publicationsMehraveh Sadeghi Ivraghi
School of Medicine Qazvin University of Medical Sciences Qazvin Iran
10 shared publicationsNiloofar Taheri
School of Medicine Shahroud University of Medical Sciences Shahroud Iran
8 shared publicationsBeneen M. Hussien
Medical Laboratory Technique College The Islamic University Najaf Iraq
5 shared publicationsAfsaneh Soltani
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 shared publications
Latest Publications
- 3 September 2025
- Published by Wiley in BioFactors
- Vol. 51 (5) , e70047
The Therapeutic Potential of Flavonols in Alzheimer's Disease: Inhibiting Amyloid‐β, Oxidative Stress, and Neuroinflammation
Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by amyloid‐β (Aβ) aggregation, oxidative stress, and neuroinflammation, remains a significant global health challenge. This study investigates the therapeutic potential of flavonols—quercetin, kaempferol, myricetin, and fisetin—in targeting Aβ aggregation and mitigating AD pathology through diverse molecular mechanisms. Our findings reveal that flavonols effectively inhibit Aβ oligomerization and fibril formation, reduce oxidative stress via Nrf2/HO‐1 pathway activation, and suppress neuroinflammation by modulating microglial polarization. Additionally, these compounds enhance mitochondrial function, promote autophagy‐mediated clearance of Aβ aggregates, and regulate key enzymes such as β‐secretase (BACE1) and α‐secretases (ADAM10/17), favoring non‐amyloidogenic pathways. Quercetin demonstrated neuroprotective effects by activating TrkB signaling, reducing tau phosphorylation, and enhancing synaptic plasticity. Kaempferol prevented Aβ‐induced apoptosis via the ER/ERK/MAPK pathway and inhibited acetylcholinesterase activity, improving cognitive outcomes. Myricetin ameliorated mitochondrial dysfunction and oxidative damage through GSK3β/ERK2 signaling modulation and showed enhanced brain bioavailability when delivered via nanostructured lipid carriers. Fisetin reduced Aβ burden by upregulating neprilysin expression, suppressed neuroinflammation, and improved synaptic function by restoring synaptic protein levels. Overall, flavonols exhibit multi‐targeted therapeutic potential against AD by addressing its complex pathogenesis. Their ability to cross the blood–brain barrier and low toxicity profiles position them as promising candidates for further clinical development. This study underscores the potential of flavonols as natural agents for AD treatment and highlights their role in advancing multi‐mechanistic therapeutic strategies.
- 3 September 2025
- Published by Wiley in BioFactors
- Vol. 51 (5) , e70047
The Therapeutic Potential of Flavonols in Alzheimer's Disease: Inhibiting Amyloid‐β, Oxidative Stress, and Neuroinflammation
Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by amyloid‐β (Aβ) aggregation, oxidative stress, and neuroinflammation, remains a significant global health challenge. This study investigates the therapeutic potential of flavonols—quercetin, kaempferol, myricetin, and fisetin—in targeting Aβ aggregation and mitigating AD pathology through diverse molecular mechanisms. Our findings reveal that flavonols effectively inhibit Aβ oligomerization and fibril formation, reduce oxidative stress via Nrf2/HO‐1 pathway activation, and suppress neuroinflammation by modulating microglial polarization. Additionally, these compounds enhance mitochondrial function, promote autophagy‐mediated clearance of Aβ aggregates, and regulate key enzymes such as β‐secretase (BACE1) and α‐secretases (ADAM10/17), favoring non‐amyloidogenic pathways. Quercetin demonstrated neuroprotective effects by activating TrkB signaling, reducing tau phosphorylation, and enhancing synaptic plasticity. Kaempferol prevented Aβ‐induced apoptosis via the ER/ERK/MAPK pathway and inhibited acetylcholinesterase activity, improving cognitive outcomes. Myricetin ameliorated mitochondrial dysfunction and oxidative damage through GSK3β/ERK2 signaling modulation and showed enhanced brain bioavailability when delivered via nanostructured lipid carriers. Fisetin reduced Aβ burden by upregulating neprilysin expression, suppressed neuroinflammation, and improved synaptic function by restoring synaptic protein levels. Overall, flavonols exhibit multi‐targeted therapeutic potential against AD by addressing its complex pathogenesis. Their ability to cross the blood–brain barrier and low toxicity profiles position them as promising candidates for further clinical development. This study underscores the potential of flavonols as natural agents for AD treatment and highlights their role in advancing multi‐mechanistic therapeutic strategies.
- Open Access
- 25 August 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (9)
Curcumin and Resveratrol as Dual Modulators of the STAT 3 Pathway in Lung Cancer: A Comprehensive Review
Lung cancer, primarily consisting of nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC), remains a significant health challenge despite advancements in treatment. This comprehensive review investigates the therapeutic potential of natural compounds curcumin (CUR) and resveratrol (RES) in targeting the STAT3 signaling pathway, which plays a crucial role in lung cancer progression and metastasis. Specifically, CUR inhibits STAT3 phosphorylation and activation in lung cancer cells, leading to a 40%–60% reduction in tumor size and a significant decrease in the expression of STAT3 target genes such as cyclin D1, VEGF, MMP2, and MMP9. RES demonstrates similar effects by suppressing STAT3 signaling, resulting in a 30%–50% reduction in tumor growth and a marked decrease in the M2 polarization of tumor‐associated macrophages, thereby disrupting the communication between cancer cells and the tumor microenvironment. CUR analogues, such as L48H37 and compound 5 k, also exhibit anticancer effects by blocking the STAT3 pathway. L48H37 suppresses the motility, migration, and invasion of human osteosarcoma cells by inhibiting the JAK/STAT pathway and urokinase plasminogen activator (uPA) expression. Compound 5 k inhibits NSCLC cell growth by regulating the NF‐κB/STAT3 signaling pathways. RES inhibits STAT3 activation and downstream signaling in NSCLC cells, reducing cell migration and invasion while increasing apoptosis by 20%–30%. In vivo studies show that RES can suppress tumor growth by 40%–50% by inhibiting the STAT3/HIF‐1α/VEGF axis. RES also shows promise in overcoming drug resistance in SCLC by inhibiting the STAT3/VEGF pathway and P‐glycoprotein function, potentially resensitizing resistant cells to chemotherapy. These findings underscore the potential of CUR and RES as promising therapeutic agents against lung cancer by targeting the STAT3 signaling pathway and related processes such as angiogenesis, metastasis, and drug resistance. Further research is needed to optimize their bioavailability, understand their molecular mechanisms, and assess their clinical efficacy in combination with standard therapies.
- 25 August 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (9)
Open AccessCurcumin and Resveratrol as Dual Modulators of the STAT 3 Pathway in Lung Cancer: A Comprehensive Review
Lung cancer, primarily consisting of nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC), remains a significant health challenge despite advancements in treatment. This comprehensive review investigates the therapeutic potential of natural compounds curcumin (CUR) and resveratrol (RES) in targeting the STAT3 signaling pathway, which plays a crucial role in lung cancer progression and metastasis. Specifically, CUR inhibits STAT3 phosphorylation and activation in lung cancer cells, leading to a 40%–60% reduction in tumor size and a significant decrease in the expression of STAT3 target genes such as cyclin D1, VEGF, MMP2, and MMP9. RES demonstrates similar effects by suppressing STAT3 signaling, resulting in a 30%–50% reduction in tumor growth and a marked decrease in the M2 polarization of tumor‐associated macrophages, thereby disrupting the communication between cancer cells and the tumor microenvironment. CUR analogues, such as L48H37 and compound 5 k, also exhibit anticancer effects by blocking the STAT3 pathway. L48H37 suppresses the motility, migration, and invasion of human osteosarcoma cells by inhibiting the JAK/STAT pathway and urokinase plasminogen activator (uPA) expression. Compound 5 k inhibits NSCLC cell growth by regulating the NF‐κB/STAT3 signaling pathways. RES inhibits STAT3 activation and downstream signaling in NSCLC cells, reducing cell migration and invasion while increasing apoptosis by 20%–30%. In vivo studies show that RES can suppress tumor growth by 40%–50% by inhibiting the STAT3/HIF‐1α/VEGF axis. RES also shows promise in overcoming drug resistance in SCLC by inhibiting the STAT3/VEGF pathway and P‐glycoprotein function, potentially resensitizing resistant cells to chemotherapy. These findings underscore the potential of CUR and RES as promising therapeutic agents against lung cancer by targeting the STAT3 signaling pathway and related processes such as angiogenesis, metastasis, and drug resistance. Further research is needed to optimize their bioavailability, understand their molecular mechanisms, and assess their clinical efficacy in combination with standard therapies.
- Open Access
- 11 August 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 31211
Biomarkers for colorectal cancer detection: An insight into colorectal cancer and FDA-approved biomarkers
Colorectal cancer (CRC) constitutes a significant global health challenge, accounting for a considerable proportion of cancer cases and associated mortality. Projections indicate a potential increase in new cases by 2040, attributed to demographic factors such as aging and population growth. Although advancements in the understanding of CRC pathophysiology have broadened treatment options, challenges such as drug resistance and adverse effects persist, highlighting the necessity for enhanced diagnostic methodologies. Timely detection markedly improves survival rates; however, colonoscopy, regarded as the gold standard for CRC screening, is constrained by its invasiveness and reliance on practitioner expertise. Consequently, the development of novel diagnostic approaches is imperative. Cancer biomarkers, which serve as indicators of cancer progression, show significant promise for improving diagnosis, prognosis, and treatment strategies. This study investigates molecular and cellular biomarkers, including proteins, DNA mutations, methylation markers, and microRNAs, that are pivotal in precision medicine and the monitoring of CRC progression. Additionally, emerging biomarkers such as circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs) present opportunities for early detection. Current Food and Drug Administration (FDA)-approved CRC biomarkers reflect a shift towards personalized medicine, enhancing patient compliance and clinical outcomes. Nevertheless, further research is essential for the discovery of novel biomarkers and for deepening the understanding of CRC etiology, thereby advancing personalized care. Addressing standardization challenges will be crucial for ensuring global patient access to biomarker-based strategies.
- 11 August 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 31211
Open AccessBiomarkers for colorectal cancer detection: An insight into colorectal cancer and FDA-approved biomarkers
Colorectal cancer (CRC) constitutes a significant global health challenge, accounting for a considerable proportion of cancer cases and associated mortality. Projections indicate a potential increase in new cases by 2040, attributed to demographic factors such as aging and population growth. Although advancements in the understanding of CRC pathophysiology have broadened treatment options, challenges such as drug resistance and adverse effects persist, highlighting the necessity for enhanced diagnostic methodologies. Timely detection markedly improves survival rates; however, colonoscopy, regarded as the gold standard for CRC screening, is constrained by its invasiveness and reliance on practitioner expertise. Consequently, the development of novel diagnostic approaches is imperative. Cancer biomarkers, which serve as indicators of cancer progression, show significant promise for improving diagnosis, prognosis, and treatment strategies. This study investigates molecular and cellular biomarkers, including proteins, DNA mutations, methylation markers, and microRNAs, that are pivotal in precision medicine and the monitoring of CRC progression. Additionally, emerging biomarkers such as circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs) present opportunities for early detection. Current Food and Drug Administration (FDA)-approved CRC biomarkers reflect a shift towards personalized medicine, enhancing patient compliance and clinical outcomes. Nevertheless, further research is essential for the discovery of novel biomarkers and for deepening the understanding of CRC etiology, thereby advancing personalized care. Addressing standardization challenges will be crucial for ensuring global patient access to biomarker-based strategies.
- Open Access
- 22 May 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (5) , e70153
A Comprehensive Review of Two‐Dimensional Speckle‐Tracking Echocardiography in Assessing Right and Left Ventricular Function in Diabetic Patients
Background: Two‐dimensional speckle‐tracking echocardiography (2D‐STE) has emerged as a valuable tool for assessing cardiac function in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM).Hypothesis: This review synthesizes recent studies utilizing 2D‐STE in diabetic patients, highlighting its clinical applications and findings.Methods: In this review, relevant studies were identified through comprehensive searches of major scientific databases, including PubMed, Scopus, Google Scholar, ScienceDirect, and other reputable sources.Results: The results of this study indicate that 2D‐STE is capable of detecting subclinical cardiac dysfunction in patients with both T1DM and T2DM, even in instances where conventional echocardiographic parameters appear to be within normal limits. Assessment of right ventricular (RV) function through 2D‐STE has demonstrated impaired right ventricular free wall longitudinal strain (RVFWLS) and global longitudinal strain (RVGLS) in individuals with T2DM, which correlates with suboptimal glycemic control. Furthermore, evaluation of left ventricular (LV) function has revealed decreased global longitudinal strain (GLS) and impaired LV twist mechanics in T2DM patients, particularly under conditions of physiological stress.In T1DM patients, 2D‐STE has identified early changes in myocardial deformation, with studies reporting reduced LV and RV strain values compared to healthy controls. The technique has also been effective in assessing the impact of disease duration and glycemic control on cardiac function in both T1DM and T2DM.Conclusions: These findings underscore the potential of 2D‐STE as a sensitive and comprehensive tool for early detection of cardiac dysfunction in both T1DM and T2DM, potentially guiding management strategies and improving outcomes in these high‐risk populations.
- 22 May 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (5) , e70153
Open AccessA Comprehensive Review of Two‐Dimensional Speckle‐Tracking Echocardiography in Assessing Right and Left Ventricular Function in Diabetic Patients
Background: Two‐dimensional speckle‐tracking echocardiography (2D‐STE) has emerged as a valuable tool for assessing cardiac function in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM).Hypothesis: This review synthesizes recent studies utilizing 2D‐STE in diabetic patients, highlighting its clinical applications and findings.Methods: In this review, relevant studies were identified through comprehensive searches of major scientific databases, including PubMed, Scopus, Google Scholar, ScienceDirect, and other reputable sources.Results: The results of this study indicate that 2D‐STE is capable of detecting subclinical cardiac dysfunction in patients with both T1DM and T2DM, even in instances where conventional echocardiographic parameters appear to be within normal limits. Assessment of right ventricular (RV) function through 2D‐STE has demonstrated impaired right ventricular free wall longitudinal strain (RVFWLS) and global longitudinal strain (RVGLS) in individuals with T2DM, which correlates with suboptimal glycemic control. Furthermore, evaluation of left ventricular (LV) function has revealed decreased global longitudinal strain (GLS) and impaired LV twist mechanics in T2DM patients, particularly under conditions of physiological stress.In T1DM patients, 2D‐STE has identified early changes in myocardial deformation, with studies reporting reduced LV and RV strain values compared to healthy controls. The technique has also been effective in assessing the impact of disease duration and glycemic control on cardiac function in both T1DM and T2DM.Conclusions: These findings underscore the potential of 2D‐STE as a sensitive and comprehensive tool for early detection of cardiac dysfunction in both T1DM and T2DM, potentially guiding management strategies and improving outcomes in these high‐risk populations.
- 24 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (9) , 11145-11160
Omentin-1 as a promising biomarker and therapeutic target in hypertension and heart failure: a comprehensive review
Omentin-1, a novel adipocytokine predominantly secreted by visceral adipose tissue, has emerged as a significant factor in cardiovascular health, particularly regarding hypertension (HTN) and heart failure (HF). This manuscript investigates the multifaceted roles of omentin-1 in these conditions, emphasizing its protective effects on vascular function and its potential as both a biomarker and therapeutic target. Clinical studies indicate that reduced circulating levels of omentin-1 are associated with metabolic syndrome (MetS) and increased cardiovascular risk, while animal studies demonstrate its ability to ameliorate endothelial dysfunction and lower blood pressure. Omentin-1 exerts its beneficial effects through various signaling pathways, including AMP-activated protein kinase (AMPK) and protein kinase B (Akt), thereby promoting vasodilation, enhancing insulin sensitivity, and mitigating inflammation. In the context of HF, particularly heart failure with preserved ejection fraction (HFpEF), omentin-1 levels exhibit a negative correlation with diastolic dysfunction and inflammatory markers, suggesting its role in cardiac protection. Additionally, the manuscript discusses the implications of omentin-1 in managing obesity-related cardiovascular diseases and its potential utility as a prognostic marker for adverse outcomes in HF patients. Collectively, omentin-1 represents a promising avenue for research in cardiovascular health, with the potential to inform novel therapeutic strategies aimed at improving outcomes in patients with HTN and HF. Further research is necessary to elucidate the details of omentin-1 function and evaluate its potential in the treatment of cardiovascular disease. Graphical abstract Omentin-1 is an adipokine secreted from adipose tissue that plays crucial roles in cardiovascular health. This protein demonstrates significant cardioprotective effects by reducing inflammation, cardiac hypertrophy, and myocardial infarction risks. On the vascular side, Omentin-1 helps improve endothelial function while reducing arterial stiffness, vascular tone, and insulin resistance. Notably, patients suffering from heart failure and hypertension typically show lower levels of Omentin-1 compared to healthy individuals. The therapeutic potential of Omentin-1 is particularly promising, as treatment with this protein has shown effectiveness in improving patient outcomes. The diagram illustrates how Omentin-1 functions as a mediator between adipose tissue and cardiovascular health through multiple pathways. The protein’s dual action on both cardiac and vascular systems makes it an important target for cardiovascular disease treatment. The upward and downward arrows in the figure effectively demonstrate how Omentin-1 enhances beneficial functions while suppressing harmful cardiovascular conditions.
- 24 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (9) , 11145-11160
Omentin-1 as a promising biomarker and therapeutic target in hypertension and heart failure: a comprehensive review
Omentin-1, a novel adipocytokine predominantly secreted by visceral adipose tissue, has emerged as a significant factor in cardiovascular health, particularly regarding hypertension (HTN) and heart failure (HF). This manuscript investigates the multifaceted roles of omentin-1 in these conditions, emphasizing its protective effects on vascular function and its potential as both a biomarker and therapeutic target. Clinical studies indicate that reduced circulating levels of omentin-1 are associated with metabolic syndrome (MetS) and increased cardiovascular risk, while animal studies demonstrate its ability to ameliorate endothelial dysfunction and lower blood pressure. Omentin-1 exerts its beneficial effects through various signaling pathways, including AMP-activated protein kinase (AMPK) and protein kinase B (Akt), thereby promoting vasodilation, enhancing insulin sensitivity, and mitigating inflammation. In the context of HF, particularly heart failure with preserved ejection fraction (HFpEF), omentin-1 levels exhibit a negative correlation with diastolic dysfunction and inflammatory markers, suggesting its role in cardiac protection. Additionally, the manuscript discusses the implications of omentin-1 in managing obesity-related cardiovascular diseases and its potential utility as a prognostic marker for adverse outcomes in HF patients. Collectively, omentin-1 represents a promising avenue for research in cardiovascular health, with the potential to inform novel therapeutic strategies aimed at improving outcomes in patients with HTN and HF. Further research is necessary to elucidate the details of omentin-1 function and evaluate its potential in the treatment of cardiovascular disease. Graphical abstract Omentin-1 is an adipokine secreted from adipose tissue that plays crucial roles in cardiovascular health. This protein demonstrates significant cardioprotective effects by reducing inflammation, cardiac hypertrophy, and myocardial infarction risks. On the vascular side, Omentin-1 helps improve endothelial function while reducing arterial stiffness, vascular tone, and insulin resistance. Notably, patients suffering from heart failure and hypertension typically show lower levels of Omentin-1 compared to healthy individuals. The therapeutic potential of Omentin-1 is particularly promising, as treatment with this protein has shown effectiveness in improving patient outcomes. The diagram illustrates how Omentin-1 functions as a mediator between adipose tissue and cardiovascular health through multiple pathways. The protein’s dual action on both cardiac and vascular systems makes it an important target for cardiovascular disease treatment. The upward and downward arrows in the figure effectively demonstrate how Omentin-1 enhances beneficial functions while suppressing harmful cardiovascular conditions.
- 3 March 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 61 (5) , e70034
The Roles of Neuroinflammation in l ‐DOPA‐Induced Dyskinesia: Dissecting the Roles of NF‐κB and TNF‐α for Novel Pharmacological Therapeutic Approaches
Levodopa‐induced dyskinesia (LID) is a common and debilitating complication of long‐term Parkinson's disease treatment. This review explores the roles of NF‐κB and TNF‐α signalling pathways in LID pathophysiology and potential therapeutic approaches targeting these mechanisms. Chronic levodopa treatment leads to aberrant neuroplasticity and neuroinflammation, involving activation of NF‐κB and increased production of pro‐inflammatory cytokines like TNF‐α. NF‐κB activation in glial cells contributes to sustained neuroinflammation and exacerbates dopaminergic neuron loss. TNF‐α levels are elevated in brain regions affected by LID and correlate with dyskinesia severity. Several compounds are involved in mitigating LID by modulating these pathways. Agmatine reduces NF‐κB activation and NMDA receptor expression while protecting dopaminergic neurons. Resveratrol and doxycycline demonstrate antidyskinetic effects by attenuating neuroinflammation and TNF‐α production. The Rho‐kinase (ROCK) inhibitor fasudil and cannabinoid receptor 2 (CB2) receptor agonists also show efficacy in reducing LID severity and neuroinflammation. Hydrogen gas inhalation decreases pro‐inflammatory cytokine levels associated with LID. These findings highlight the complex interplay between NF‐κB, TNF‐α and other neurotransmitter systems in LID pathogenesis. Targeting neuroinflammation and glial activation through these pathways represents a promising strategy for developing novel LID treatments. Further research is needed to fully elucidate the mechanisms and optimize therapeutic approaches targeting NF‐κB and TNF‐α signalling in LID.
- 3 March 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 61 (5) , e70034
The Roles of Neuroinflammation in l ‐DOPA‐Induced Dyskinesia: Dissecting the Roles of NF‐κB and TNF‐α for Novel Pharmacological Therapeutic Approaches
Levodopa‐induced dyskinesia (LID) is a common and debilitating complication of long‐term Parkinson's disease treatment. This review explores the roles of NF‐κB and TNF‐α signalling pathways in LID pathophysiology and potential therapeutic approaches targeting these mechanisms. Chronic levodopa treatment leads to aberrant neuroplasticity and neuroinflammation, involving activation of NF‐κB and increased production of pro‐inflammatory cytokines like TNF‐α. NF‐κB activation in glial cells contributes to sustained neuroinflammation and exacerbates dopaminergic neuron loss. TNF‐α levels are elevated in brain regions affected by LID and correlate with dyskinesia severity. Several compounds are involved in mitigating LID by modulating these pathways. Agmatine reduces NF‐κB activation and NMDA receptor expression while protecting dopaminergic neurons. Resveratrol and doxycycline demonstrate antidyskinetic effects by attenuating neuroinflammation and TNF‐α production. The Rho‐kinase (ROCK) inhibitor fasudil and cannabinoid receptor 2 (CB2) receptor agonists also show efficacy in reducing LID severity and neuroinflammation. Hydrogen gas inhalation decreases pro‐inflammatory cytokine levels associated with LID. These findings highlight the complex interplay between NF‐κB, TNF‐α and other neurotransmitter systems in LID pathogenesis. Targeting neuroinflammation and glial activation through these pathways represents a promising strategy for developing novel LID treatments. Further research is needed to fully elucidate the mechanisms and optimize therapeutic approaches targeting NF‐κB and TNF‐α signalling in LID.
- 31 January 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (6) , 7393-7412
The Role of ΔFosB in the Pathogenesis of Levodopa-Induced Dyskinesia: Mechanisms and Therapeutic Strategies
Levodopa-induced dyskinesia (LID) represents a significant complication associated with the long-term administration of levodopa (L-DOPA) for the treatment of Parkinson’s disease (PD). This review examines the critical role of ΔFosB, a transcription factor, in the pathogenesis of LID and explores potential therapeutic interventions. ΔFosB accumulates within the striatum in response to chronic dopaminergic stimulation, thereby driving maladaptive changes that culminate in dyskinesia. Its persistent expression modifies gene transcription, influencing neuronal plasticity and contributing to the sustained presence of dyskinetic movements. This study explains how ΔFosB functions at the molecular level, focusing on its connections with dopamine D1 receptors, the cAMP/PKA signaling pathway, and its regulatory effects on downstream targets such as DARPP-32 and GluA1 AMPA receptor subunits. Additionally, it examines how neuronal nitric oxide synthase (nNOS) affects ΔFosB levels and the development of LID. This review also considers the interactions between ΔFosB and other signaling pathways, such as ERK and mTOR, in the context of LID and striatal plasticity. Emerging therapeutic strategies targeting ΔFosB and its associated pathways include pharmacological interventions like ranitidine, 5-hydroxytryptophan, and carnosic acid. Furthermore, this study addresses the role of JunD, another component of the AP-1 transcription factor complex, in the pathogenesis of LID. Understanding the molecular mechanisms by which ΔFosB contributes to LID offers promising avenues for developing novel treatments that could mitigate dyskinesia and improve the quality of life for PD patients undergoing long-term L-DOPA therapy. Graphical Abstract
- 31 January 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (6) , 7393-7412
The Role of ΔFosB in the Pathogenesis of Levodopa-Induced Dyskinesia: Mechanisms and Therapeutic Strategies
Levodopa-induced dyskinesia (LID) represents a significant complication associated with the long-term administration of levodopa (L-DOPA) for the treatment of Parkinson’s disease (PD). This review examines the critical role of ΔFosB, a transcription factor, in the pathogenesis of LID and explores potential therapeutic interventions. ΔFosB accumulates within the striatum in response to chronic dopaminergic stimulation, thereby driving maladaptive changes that culminate in dyskinesia. Its persistent expression modifies gene transcription, influencing neuronal plasticity and contributing to the sustained presence of dyskinetic movements. This study explains how ΔFosB functions at the molecular level, focusing on its connections with dopamine D1 receptors, the cAMP/PKA signaling pathway, and its regulatory effects on downstream targets such as DARPP-32 and GluA1 AMPA receptor subunits. Additionally, it examines how neuronal nitric oxide synthase (nNOS) affects ΔFosB levels and the development of LID. This review also considers the interactions between ΔFosB and other signaling pathways, such as ERK and mTOR, in the context of LID and striatal plasticity. Emerging therapeutic strategies targeting ΔFosB and its associated pathways include pharmacological interventions like ranitidine, 5-hydroxytryptophan, and carnosic acid. Furthermore, this study addresses the role of JunD, another component of the AP-1 transcription factor complex, in the pathogenesis of LID. Understanding the molecular mechanisms by which ΔFosB contributes to LID offers promising avenues for developing novel treatments that could mitigate dyskinesia and improve the quality of life for PD patients undergoing long-term L-DOPA therapy. Graphical Abstract
- Open Access
- 3 December 2024
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 8 (1) , 5-19
Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 0.46% of the global population. Conventional therapeutics for RA, including disease‐modifying antirheumatic drugs (DMARDs), nonsteroidal anti‐inflammatory drugs (NSAIDs), and corticosteroids, frequently result in unintended adverse effects. Dexamethasone (DEX) is a potent glucocorticoid used to treat RA due to its anti‐inflammatory and immunosuppressive properties. Liposomal delivery of DEX, particularly when liposomes are surface‐modified with targeting ligands like peptides or sialic acid, can improve drug efficacy by enhancing its distribution to inflamed joints and minimizing toxicity. This study investigates the potential of liposomal drug delivery systems to enhance the efficacy and targeting of DEX in the treatment of RA. Results from various studies demonstrate that liposomal DEX significantly inhibits arthritis progression in animal models, reduces joint inflammation and damage, and alleviates cartilage destruction compared to free DEX. The liposomal formulation also shows better hemocompatibility, fewer adverse effects on body weight and immune organ index, and a longer circulation time with higher bioavailability. The anti‐inflammatory mechanism is associated with the downregulation of pro‐inflammatory cytokines like tumor necrosis factor‐α (TNF‐α) and B‐cell–activating factor (BAFF), which are key players in the pathogenesis of RA. Additionally, liposomal DEX can induce the expression of anti‐inflammatory cytokines like interleukin‐10 (IL‐10), which has significant anti‐inflammatory and immunoregulatory properties. The findings suggest that liposomal DEX represents a promising candidate for effective and safe RA therapy, with the potential to improve the management of this debilitating disease by providing targeted delivery and sustained release of the drug.
- 3 December 2024
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 8 (1) , 5-19
Open AccessImproving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 0.46% of the global population. Conventional therapeutics for RA, including disease‐modifying antirheumatic drugs (DMARDs), nonsteroidal anti‐inflammatory drugs (NSAIDs), and corticosteroids, frequently result in unintended adverse effects. Dexamethasone (DEX) is a potent glucocorticoid used to treat RA due to its anti‐inflammatory and immunosuppressive properties. Liposomal delivery of DEX, particularly when liposomes are surface‐modified with targeting ligands like peptides or sialic acid, can improve drug efficacy by enhancing its distribution to inflamed joints and minimizing toxicity. This study investigates the potential of liposomal drug delivery systems to enhance the efficacy and targeting of DEX in the treatment of RA. Results from various studies demonstrate that liposomal DEX significantly inhibits arthritis progression in animal models, reduces joint inflammation and damage, and alleviates cartilage destruction compared to free DEX. The liposomal formulation also shows better hemocompatibility, fewer adverse effects on body weight and immune organ index, and a longer circulation time with higher bioavailability. The anti‐inflammatory mechanism is associated with the downregulation of pro‐inflammatory cytokines like tumor necrosis factor‐α (TNF‐α) and B‐cell–activating factor (BAFF), which are key players in the pathogenesis of RA. Additionally, liposomal DEX can induce the expression of anti‐inflammatory cytokines like interleukin‐10 (IL‐10), which has significant anti‐inflammatory and immunoregulatory properties. The findings suggest that liposomal DEX represents a promising candidate for effective and safe RA therapy, with the potential to improve the management of this debilitating disease by providing targeted delivery and sustained release of the drug.
- Open Access
- 26 October 2024
- Published by Wiley in Food Science & Nutrition
- Vol. 12 (11) , 9834-9845
The Impact of Vitamin E Supplementation on Oxidative Stress, Cognitive Functions, and Aging‐Related Gene Expression in Aged Mice
This study investigated the effects of different doses of vitamin E on oxidative stress, cognitive function, and gene expression in aged mice. A total of 32 male mice, aged 12 months, were divided into a control group and three treatment groups. These groups received varying daily doses of vitamin E for a period of 28 days. The results showed significant improvements in cognitive function, specifically in working memory and spatial learning, in the groups that received vitamin E (100, 200, or 400 mg/kg) compared to the control group. The markers of oxidative stress and antioxidant enzyme activities also demonstrated improvements, with higher doses of vitamin E showing greater effects. The analysis of gene expression revealed increased expression of SIRT1, Nrf2, and Calstabin2, particularly at higher doses of vitamin E. These findings suggest that vitamin E supplementation may help counteract age‐related cellular changes. The study concludes that vitamin E supplementation can reduce oxidative stress, enhance cognitive function, and affect genetic markers of aging in mice, which may have therapeutic benefits in addressing age‐related cognitive decline and oxidative damage. Further research is necessary to investigate the clinical implications of these findings in humans.
- 26 October 2024
- Published by Wiley in Food Science & Nutrition
- Vol. 12 (11) , 9834-9845
Open AccessThe Impact of Vitamin E Supplementation on Oxidative Stress, Cognitive Functions, and Aging‐Related Gene Expression in Aged Mice
This study investigated the effects of different doses of vitamin E on oxidative stress, cognitive function, and gene expression in aged mice. A total of 32 male mice, aged 12 months, were divided into a control group and three treatment groups. These groups received varying daily doses of vitamin E for a period of 28 days. The results showed significant improvements in cognitive function, specifically in working memory and spatial learning, in the groups that received vitamin E (100, 200, or 400 mg/kg) compared to the control group. The markers of oxidative stress and antioxidant enzyme activities also demonstrated improvements, with higher doses of vitamin E showing greater effects. The analysis of gene expression revealed increased expression of SIRT1, Nrf2, and Calstabin2, particularly at higher doses of vitamin E. These findings suggest that vitamin E supplementation may help counteract age‐related cellular changes. The study concludes that vitamin E supplementation can reduce oxidative stress, enhance cognitive function, and affect genetic markers of aging in mice, which may have therapeutic benefits in addressing age‐related cognitive decline and oxidative damage. Further research is necessary to investigate the clinical implications of these findings in humans.
- Open Access
- 24 October 2024
- Published by Wiley in Food Science & Nutrition
- Vol. 12 (11) , 8825-8845
Effects of Resveratrol on Nonmelanoma Skin Cancer ( NMSC ): A Comprehensive Review
Nonmelanoma skin cancer (NMSC) represents the most prevalent form of skin cancer globally, with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) being the most common types. The search for effective chemopreventive and therapeutic agents has led to the exploration of natural compounds, among which resveratrol (RES), a polyphenolic phytoalexin found in grapes, berries, peanuts, and red wine, has garnered significant attention. This comprehensive review aims to elucidate the effects of RES on NMSC, focusing on its mechanisms of action, efficacy in preclinical studies, and potential as a chemopreventive and therapeutic agent. RES exhibits promising chemopreventive and antineoplastic capabilities against NMSC through various mechanisms, including the induction of apoptosis, inhibition of cell proliferation, modulation of oxidative stress, and anti‐inflammatory activities. Studies have demonstrated that RES can significantly enhance the effectiveness of traditional chemotherapeutic agents, such as 5‐fluorouracil (5‐FU), by inhibiting cellular proliferation and inducing apoptosis in cancerous cells. Furthermore, resveratrol's antioxidant properties may mitigate the impact of reactive oxygen species (ROS) triggered by UV exposure, thus reducing DNA damage and mutations associated with skin cancer development. In vitro and in vivo experiments have shown that RES can effectively hinder the growth and spread of various tumor cell types, including human cutaneous SCC A431 cells, and induce apoptosis. The development of advanced delivery systems, such as nanostructured lipid carriers and liposomes, has been recognized for their potential to enhance the therapeutic effects of RES, particularly its anticancer properties. In conclusion, RES presents a viable candidate for the prevention and treatment of NMSC, owing to its multifaceted mechanisms of action, including its ability to regulate oxidative stress, trigger apoptosis, and inhibit proliferation. However, further clinical studies are required to fully understand its effectiveness and safety in humans, as well as to optimize delivery methods for improved bioavailability and therapeutic outcomes.
- 24 October 2024
- Published by Wiley in Food Science & Nutrition
- Vol. 12 (11) , 8825-8845
Open AccessEffects of Resveratrol on Nonmelanoma Skin Cancer ( NMSC ): A Comprehensive Review
Nonmelanoma skin cancer (NMSC) represents the most prevalent form of skin cancer globally, with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) being the most common types. The search for effective chemopreventive and therapeutic agents has led to the exploration of natural compounds, among which resveratrol (RES), a polyphenolic phytoalexin found in grapes, berries, peanuts, and red wine, has garnered significant attention. This comprehensive review aims to elucidate the effects of RES on NMSC, focusing on its mechanisms of action, efficacy in preclinical studies, and potential as a chemopreventive and therapeutic agent. RES exhibits promising chemopreventive and antineoplastic capabilities against NMSC through various mechanisms, including the induction of apoptosis, inhibition of cell proliferation, modulation of oxidative stress, and anti‐inflammatory activities. Studies have demonstrated that RES can significantly enhance the effectiveness of traditional chemotherapeutic agents, such as 5‐fluorouracil (5‐FU), by inhibiting cellular proliferation and inducing apoptosis in cancerous cells. Furthermore, resveratrol's antioxidant properties may mitigate the impact of reactive oxygen species (ROS) triggered by UV exposure, thus reducing DNA damage and mutations associated with skin cancer development. In vitro and in vivo experiments have shown that RES can effectively hinder the growth and spread of various tumor cell types, including human cutaneous SCC A431 cells, and induce apoptosis. The development of advanced delivery systems, such as nanostructured lipid carriers and liposomes, has been recognized for their potential to enhance the therapeutic effects of RES, particularly its anticancer properties. In conclusion, RES presents a viable candidate for the prevention and treatment of NMSC, owing to its multifaceted mechanisms of action, including its ability to regulate oxidative stress, trigger apoptosis, and inhibit proliferation. However, further clinical studies are required to fully understand its effectiveness and safety in humans, as well as to optimize delivery methods for improved bioavailability and therapeutic outcomes.